124 related articles for article (PubMed ID: 17417790)
1. Successful treatment of refractory immune hemolysis following unrelated cord blood transplant with Campath-1H.
Chao MM; Levine JE; Ferrara JL; Cooling L; Cooke KR; Hutchinson RJ; Yanik GA
Pediatr Blood Cancer; 2008 Apr; 50(4):917-9. PubMed ID: 17417790
[TBL] [Abstract][Full Text] [Related]
2. Severe autoimmune hemolytic anemia after unrelated umbilical cord blood transplant for familial hemophagocytic lymphohistiocytosis: significant improvement after treatment with rituximab.
Radhi M; Rumelhart S; Tatman D; Goldman F
J Pediatr Hematol Oncol; 2007 Feb; 29(2):125-7. PubMed ID: 17279011
[TBL] [Abstract][Full Text] [Related]
3. The effect of treatment with Campath-1H in patients with autoimmune cytopenias.
Willis F; Marsh JC; Bevan DH; Killick SB; Lucas G; Griffiths R; Ouwehand W; Hale G; Waldmann H; Gordon-Smith EC
Br J Haematol; 2001 Sep; 114(4):891-8. PubMed ID: 11564082
[TBL] [Abstract][Full Text] [Related]
4. Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.
Raj K; Narayanan S; Augustson B; Ho A; Mehta P; Duncan N; Tauro S; Mahendra P; Craddock C; Mufti G
Bone Marrow Transplant; 2005 Feb; 35(3):299-301. PubMed ID: 15568036
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune hemolysis and immune thrombocytopenic purpura after cord blood transplantation may be life-threatening and warrants early therapy with rituximab.
Bhatt V; Shune L; Lauer E; Lubin M; Devlin SM; Scaradavou A; Parameswaran R; Perales MA; Ponce DM; Mantha S; Kernan NA; Barker JN
Bone Marrow Transplant; 2016 Dec; 51(12):1579-1583. PubMed ID: 27643868
[TBL] [Abstract][Full Text] [Related]
6. Immune thrombocytopenia after umbilical cord progenitor cell transplant: response to vincristine.
Dovat S; Roberts RL; Wakim M; Stiehm ER; Feig SA
Bone Marrow Transplant; 1999 Aug; 24(3):321-3. PubMed ID: 10455373
[TBL] [Abstract][Full Text] [Related]
7. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells.
Hale G; Jacobs P; Wood L; Fibbe WE; Barge R; Novitzky N; Toit C; Abrahams L; Thomas V; Bunjes D; Duncker C; Wiesneth M; Selleslag D; Hidajat M; Starobinski M; Bird P; Waldmann H
Bone Marrow Transplant; 2000 Jul; 26(1):69-76. PubMed ID: 10918407
[TBL] [Abstract][Full Text] [Related]
8. Successful unrelated cord blood transplantation in a 7-year-old boy with Evans syndrome refractory to immunosuppression and double autologous stem cell transplantation.
Urban C; Lackner H; Sovinz P; Benesch M; Schwinger W; Dornbusch HJ; Moser A
Eur J Haematol; 2006 Jun; 76(6):526-30. PubMed ID: 16529601
[TBL] [Abstract][Full Text] [Related]
9. CAMPATH-1H in the treatment of autoimmune cytopenias.
Marsh JC; Gordon-Smith EC
Cytotherapy; 2001; 3(3):189-95. PubMed ID: 12171725
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibodies in the treatment of autoimmune cytopenias.
Robak T
Eur J Haematol; 2004 Feb; 72(2):79-88. PubMed ID: 14962245
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura in pediatric solid organ transplant recipients, report of five cases and review of the literature.
Miloh T; Arnon R; Roman E; Hurlet A; Kerkar N; Wistinghausen B
Pediatr Transplant; 2011 Dec; 15(8):870-8. PubMed ID: 22112003
[TBL] [Abstract][Full Text] [Related]
12. Successful use of rituximab in Evans syndrome and refractory immune thrombocytopenic purpura.
Kashif M; Qureshi A; Adil SN; Khurshid M
J Pak Med Assoc; 2010 Jan; 60(1):64-5. PubMed ID: 20055286
[TBL] [Abstract][Full Text] [Related]
13. The effects of Campath 1H upon graft-versus-host disease, infection, relapse, and immune reconstitution in recipients of pediatric unrelated transplants.
Shah AJ; Kapoor N; Crooks GM; Weinberg KI; Azim HA; Killen R; Kuo L; Rushing T; Kohn DB; Parkman R
Biol Blood Marrow Transplant; 2007 May; 13(5):584-93. PubMed ID: 17448918
[TBL] [Abstract][Full Text] [Related]
14. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
15. Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation.
Pratt G; Kinsey SE
Bone Marrow Transplant; 2001 Oct; 28(8):791-3. PubMed ID: 11781633
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases.
Mantadakis E; Danilatou V; Stiakaki E; Kalmanti M
Am J Hematol; 2004 Nov; 77(3):303-10. PubMed ID: 15495242
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab for B-cell chronic lymphocytic leukemia.
Robak T
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1033-51. PubMed ID: 18588450
[TBL] [Abstract][Full Text] [Related]
18. Autoimmune hematologic complications of umbilical cord blood transplantation.
Ibrahim U; Keyzner A
Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):104-109. PubMed ID: 32882204
[TBL] [Abstract][Full Text] [Related]
19. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab.
Ramanathan S; Koutts J; Hertzberg MS
Am J Hematol; 2005 Feb; 78(2):123-6. PubMed ID: 15682420
[TBL] [Abstract][Full Text] [Related]
20. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
